新闻源 财富源

2019年10月21日 星期一

康缘药业(600557)公告正文

康缘药业:2013年第三季度报告

公告日期:2013-10-25

    股票简称:康缘药业                                  股票代码:600557
              江苏康缘药业股份有限公司
                              600557
                     2013 年第三季度报告
                      二〇一三 年 十 月 二十四 日
      江苏康缘药业股份有限公司(股票代码:600557)                      2013 年第三季度报告
                                          目         录一、 重要提示......................................................................... 2二、 公司主要财务数据和股东变化 ....................................................... 2三、 重要事项......................................................................... 4四、 附录 ............................................................................ 7
           江苏康缘药业股份有限公司(股票代码:600557)                          2013 年第三季度报告
    一、    重要提示
          1.1 本公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、
    完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。
          1.2   公司全体董事出席董事会审议季度报告。
        1.3
    公司负责人姓名                                                           肖 伟
    主管会计工作负责人姓名                                                   陈友龙
    会计机构负责人(会计主管人员)姓名                                       焦晓杉
       公司负责人肖伟、主管会计工作负责人陈友龙及会计机构负责人(会计主管人员)焦晓杉
    保证季度报告中财务报表的真实、准确、完整。
          1.4   公司第三季度报告中的财务报表未经审计。
    二、 公司主要财务数据和股东变化
          2.1 主要财务数据
                                                                            单位:元 币种:人民币
                                                                                 本报告期末比上年度
                                     本报告期末                 上年度末
                                                                                     末增减(%)
    总资产                           3,334,822,633.11             3,124,858,357.72                  6.72
    归属于上市公司股东的净资产       1,805,111,082.37             1,611,170,838.86                 12.04
                                  年初至报告期末          上年初至上年报告期末
                                                                                 比上年同期增减(%)
                                    (1-9 月)               (1-9 月)
    经营活动产生的现金流量净额          285,380,670.56                95,487,797.42              198.87
                                  年初至报告期末          上年初至上年报告期末
                                                                                 比上年同期增减(%)
                                    (1-9 月)               (1-9 月)
    营业收入                         1,637,665,925.12             1,364,701,390.59                 20.00
    归属于上市公司股东的净利润          223,147,142.65              184,420,738.63                 21.00归属于上市公司股东的扣除非
                                    200,542,347.42              192,585,003.12                         4.13经常性损益的净利润
    加权平均净资产收益率(%)                    13.10                      12.22      增加 0.88 个百分点
    基本每股收益(元/股)                          0.54                       0.44                    22.73
    稀释每股收益(元/股)                          0.54                       0.44                    22.73
    扣除非经常性损益项目和金额:
                                                                          单位:元    币种:人民币
                                                              本期金额          年初至报告期末金额
                       项   目
                                                            (7-9 月)             (1-9 月)
    非流动资产处置损益                                               -121,986.40           -881,295.89
           江苏康缘药业股份有限公司(股票代码:600557)                           2013 年第三季度报告
    计入当期损益的政府补助,但与公司正常经营
    业务密切相关,符合国家政策规定、按照一定                      18,184,258.35         28,979,675.05
    标准定额或定量持续享受的政府补助除外
    除上述各项之外的其他营业外收入和支出                          -1,186,147.08         -1,247,185.86
    所得税影响额                                                  -2,640,281.23         -4,171,466.49
    少数股东权益影响额(税后)                                       -43,804.93            -74,931.58
                      合 计                                       14,192,038.71         22,604,795.23
          2.2    截至报告期末的股东总数、前十名股东、前十名无限售条件股东的持股
    情况表
                                                                                            单位:股
    股东总数(户)                                                                                      12,103
                                         前十名股东持股情况
                                                                                                  质押或冻
                                                       持股比                     持有有限售条
          股东名称                    股东性质                       持股总数                     结的股份
                                                       例(%)                        件股份数量
                                                                                                    数量
    江苏康缘集团有限责任公司           境内非国有法人         27.16    112,885,952     108,539,579        无
    连云港康贝尔医疗器械有限公司       境内非国有法人          5.32     22,132,338               0        无
    肖伟                                 境内自然人            2.84     11,808,082               0        无中国工商银行-汇添富成长焦点
                                         其他             2.24       9,304,641                0         未知股票型证券投资基金
    全国社保基金一零七组合                   其他             1.86       7,742,149                0         未知交通银行-中海优质成长证券投
                                         其他             1.76       7,307,515                0         未知资基金泰康人寿保险股份有限公司-分
                                         其他             1.28       5,340,267                0         未知红-个人分红-019L-FH002 沪中国建设银行-长城消费增值股
                                         其他             1.08       4,500,000                0         未知票型证券投资基金中国建设银行-信达澳银领先增
                                         其他             1.03       4,285,502                0         未知长股票型证券投资基金
    王武                                 未知          1.02    4,247,102                          0         未知
                             前十名无限售条件流通股股东持股情况
       股东名称(全称)            期末持有无限售条件流通股的数量                     股份种类及数量
    连云港康贝尔医疗器械有限公司                             22,132,338                     人民币普通股
    肖伟                                                     11,808,082                     人民币普通股中国工商银行-汇添富成长焦点
                                                           9,304,641                   人民币普通股股票型证券投资基金
    全国社保基金一零七组合                                     7,742,149                   人民币普通股交通银行-中海优质成长证券投
                                                           7,307,515                   人民币普通股资基金泰康人寿保险股份有限公司-分
                                                           5,340,267                   人民币普通股红-个人分红-019L-FH002 沪中国建设银行-长城消费增值股
                                                           4,500,000                   人民币普通股票型证券投资基金
             江苏康缘药业股份有限公司(股票代码:600557)                     2013 年第三季度报告
    江苏康缘集团有限责任公司                                         4,346,373           人民币普通股中国建设银行-信达澳银领先增
                                                                 4,285,502           人民币普通股长股票型证券投资基金
    王武                                                             4,247,102           人民币普通股
                                        前十大股东中,江苏康缘集团有限责任公司和肖伟先生存在关联关
                                    系,肖伟先生为江苏康缘集团有限责任公司第一大股东。公司未知其他
      上述股东关联关系
                                    股东之间、其他股东与前十名无限售条件股东之间是否存在关联关系或
      或一致行动的说明
                                    一致行动人关系;公司未知前十名无限售条件股东之间是否存在关联关
                                    系或一致行动人关系。
    三、 重要事项
            3.1   公司主要会计报表项目、财务指标重大变动的情况及原因
         √适用 □不适用
         3.1.1    截至报告期末,公司资产负债项目大幅变动的原因分析
                                                                          单位:元    币种:人民币
      报表项目             期末余额             年初余额       变动比例              变动原因
                                                                          主要系报告期内公司归还银
    货币资金                230,783,039.00      344,200,797.10     -32.95%
                                                                          行借款所致
                                                                          主要系报告期内子公司购买
    交易性金融资产           35,000,000.00
                                                                          理财产品所致
                                                                          主要系报告期内公司研发合
    预付款项                 70,637,534.87       39,743,591.54      77.73%
                                                                          作预付款项增多所致
                                                                          主要系报告期内子公司购买
    可供出售金融资产                               4,104,400.00   -100.00%
                                                                          理财产品到期所致
                                                                          主要系报告期内公司项目投
    在建工程                473,519,720.51      251,218,484.90      88.49%
                                                                          入增加所致
                                                                          主要系报告期内公司预付工
    其他非流动资产          106,462,762.23       76,898,598.35      38.45%   程项目及技术转让项目款项
                                                                          增多所致
                                                                          主要系报告期内公司原材料
    应付账款                174,581,924.65      133,206,767.08      31.06%
                                                                          采购增加所致
                                                                          主要系报告期内公司产品销
    预收款项                 51,630,550.47       28,887,835.60      78.73%
                                                                          售预收款增加所致
                                                                          主要系报告期内公司销售收
    应交税费                 57,667,402.23       39,937,516.69      44.39%
                                                                          入增长、利润增加所致
                                                                          主要系报告期内公司尚未支
    应付股利                  8,043,825.93           446,055.40   1703.32%   付完控股股东现金红利款所
                                                                          致
    一年内到期的非流                                                         主要系报告期内公司归还项
                          46,000,000.00       81,000,000.00     -43.21%
    动负债                                                                   目贷款所致
            江苏康缘药业股份有限公司(股票代码:600557)                     2013 年第三季度报告
                                                                         主要系报告期内公司理财产
    递延所得税负债                                    15,660.00   -100.00%
                                                                         品到期所致
                                                                         主要系报告期内公司收到政
    其他非流动负债            5,494,173.07         2,894,173.07     89.84%
                                                                         府补助,递延收益增加所致
       3.1.2 年初至报告期期末,公司利润表项目大幅动变动的原因分析
                                                                         单位:元    币种:人民币
    报表项目              本期金额             上期金额       变动比例              变动原因
                                                                         主要系报告期内子公司出售
    投资收益                    416,024.45            31,557.51   1218.31%
                                                                         理财产品所致
                                                                         主要系报告期内公司收回账
    资产减值损失                992,706.56         2,296,352.16    -56.77%
                                                                         龄较长的应收款项所致
                                                                         主要系报告期内公司收到国
    营业外收入               29,197,156.82       14,941,681.97      95.41%
                                                                         家项目补助增加所致
                                                                         主要系报告期内公司公益性
    营业外支出                2,345,963.52           714,295.06    228.43%
                                                                         捐赠增加所致
       3.1.3 年初至报告期期末,公司现金流量表项目大幅动变动的原因分析
                                                                         单位:元    币种:人民币
    报表项目              本期金额             上期金额       变动比例              变动原因
                                                                         主要系报告期内公司销售回经营活动产生的现
                        285,380,670.56       95,487,797.42     198.87%   款增加及应收票据贴现增加金流量净额
                                                                         所致
    筹资活动产生的现                                                         主要系报告期内公司银行借
                        -98,352,961.15       70,010,347.02    -240.48%
    金流量净额                                                               款减少所致
           3.2   重要事项进展情况及其影响和解决方案的分析说明
       √适用 □不适用
       报告期内,公司正在筹划非公开发行股票事宜,目前正在积极推进中。(详情请见 2013 年
    1 月 21 日和 2013 年 2 月 6 日刊登在《中国证券报》、《上海证券报》和上海证券交易所网站
    www.sse.com.cn 的相关公告)。
       报告期内,公司研制的“龙血竭酚类提取物原料及龙血通络胶囊”获得国家食品药品监督
    管理局颁发的新药证书及药品注册批件(原料药新药证书编号:国药证字 Z20130008、原料药
    药品批准文号:国药准字 Z20130013;制剂新药证书编号:国药证字 Z20130007、制剂药品批准
    文号:国药准字 Z20130012)。
         江苏康缘药业股份有限公司(股票代码:600557)                      2013 年第三季度报告
       3.3    公司及持股 5%以上的股东承诺事项履行情况
       √适用 □不适用
                                                                                            是否及
    承诺   承诺                                                                      是否有履
               承诺方                 承诺内容              承诺时间及期限                  时严格
    背景   类型                                                                        行期限
                                                                                              履行
                          公司在股改承诺期满之后追加承
    与股                      诺:所持康缘药业股份自 2008 年
              江苏康缘
    改相   股份               11 月 16 日起三年内不上市流通。    2008-11-16 至
              集团有限                                                              是           是
    关的   限售               公司持有的有限售条件股份限售        2011-11-16
              责任公司
    承诺                      期已满,但尚未申请上市流通,
                                 仍处于锁定状态。
                                                            承诺时间为 2012
              江苏康缘
    其他                       在增持计划实施期间及法定期限     年 4 月 24 日;期
       其他   集团有限                                                              是           是
    承诺                       内不减持其持有的本公司股票。     限为增持实施期
              责任公司
                                                            间及法定期限内
       3.4    预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相
    比发生重大变动的警示及原因说明
       □适用 √不适用
                                                                   江苏康缘药业股份有限公司
                                                                                法定代表人:肖伟
                                                                             2013 年 10 月 24 日
        江苏康缘药业股份有限公司(股票代码:600557)                        2013 年第三季度报告
    四、 附录
    4.1
                                    合并资产负债表(一)
                                       2013 年 9 月 30 日
    编制单位: 江苏康缘药业股份有限公司
                                             单位:元      币种:人民币     审计类型:未经审计
                   项 目                                 期末余额                 年初余额流动资产:
    货币资金                                             230,783,039.00           344,200,797.10
    交易性金融资产                                        35,000,000.00
    应收票据                                             411,038,310.89           530,960,722.43
    应收账款                                             900,406,622.30           761,924,032.63
    预付款项                                              70,637,534.87            39,743,591.54
    应收利息
    应收股利
    其他应收款                                              79,700,704.08          65,618,557.08
    买入返售金融资产
    存货                                                    92,492,957.93          90,391,742.15
    一年内到期的非流动资产
    其他流动资产
      流动资产合计                                     1,820,059,169.07        1,832,839,442.93非流动资产:
    可供出售金融资产                                                                4,104,400.00
    持有至到期投资
    长期应收款
    长期股权投资                                             3,968,030.47           3,985,532.04
    投资性房地产
    固定资产                                             705,644,501.13           729,056,205.68
    在建工程                                             473,519,720.51           251,218,484.90
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                             126,018,581.05          127,754,998.03
    开发支出                                              36,000,000.00           36,000,000.00
    商誉                                                  58,988,858.14           58,988,858.14
    长期待摊费用                                             320,088.94              320,088.94
    递延所得税资产                                         3,840,921.57            3,691,748.71
    其他非流动资产                                       106,462,762.23           76,898,598.35
      非流动资产合计                                   1,514,763,464.04        1,292,018,914.79
           资产总计                                    3,334,822,633.11        3,124,858,357.72
    公司法定代表人: 肖伟          主管会计工作负责人:陈友龙            会计机构负责人:焦晓杉
        江苏康缘药业股份有限公司(股票代码:600557)                       2013 年第三季度报告
                                    合并资产负债表(二)
                                       2013 年 9 月 30 日
    编制单位: 江苏康缘药业股份有限公司
                                              单位:元     币种:人民币    审计类型:未经审计
                   项 目                                 期末余额                年初余额流动负债:
    短期借款                                             590,000,000.00          630,350,000.00
    交易性金融负债
    应付票据                                             110,000,000.00          99,500,000.00
    应付账款                                             174,581,924.65         133,206,767.08
    预收款项                                              51,630,550.47          28,887,835.60
    应付职工薪酬                                           2,658,789.35           3,333,660.81
    应交税费                                              57,667,402.23          39,937,516.69
    应付利息                                               1,326,360.18           1,640,402.61
    应付股利                                               8,043,825.93             446,055.40
    其他应付款                                           225,513,115.56         221,336,531.75
    一年内到期的非流动负债                                46,000,000.00          81,000,000.00
    其他流动负债                                          30,194,378.90          31,357,449.78
      流动负债合计                                     1,297,616,347.27       1,270,996,219.72非流动负债:
    长期借款                                             180,000,000.00          195,000,000.00
    应付债券
    长期应付款
    专项应付款                                              5,081,854.00          5,326,346.00
    递延所得税负债                                                                   15,660.00
    其他非流动负债                                         5,494,173.07           2,894,173.07
      非流动负债合计                                     190,576,027.07         203,236,179.07
        负债合计                                       1,488,192,374.34       1,474,232,398.79所有者权益(或股东权益):
    实收资本(或股本)                                   415,646,691.00          415,646,691.00
    资本公积                                             268,152,669.08          268,208,761.63
    减:库存股
    专项储备
    盈余公积                                             141,436,348.77          141,436,348.77
    一般风险准备
    未分配利润                                           980,705,958.37         786,654,084.09
    外币报表折算差额                                        -830,584.85            -775,046.63
    归属于母公司所有者权益合计                         1,805,111,082.37       1,611,170,838.86
    少数股东权益                                          41,519,176.40          39,455,120.07
           所有者权益合计                              1,846,630,258.77       1,650,625,958.93
        负债和所有者权益总计                           3,334,822,633.11       3,124,858,357.72
    公司法定代表人: 肖伟          主管会计工作负责人:陈友龙           会计机构负责人:焦晓杉
        江苏康缘药业股份有限公司(股票代码:600557)                        2013 年第三季度报告
                                   母公司资产负债表(一)
                                       2013 年 9 月 30 日
    编制单位: 江苏康缘药业股份有限公司
                                                 单位:元 币种:人民币        审计类型:未经审计
                   项 目                                期末余额                  年初余额流动资产:
    货币资金                                             183,852,053.47           309,730,839.04
    交易性金融资产
    应收票据                                             379,483,744.02           446,715,927.70
    应收账款                                             793,652,054.91           678,074,521.94
    预付款项                                              80,109,972.20            31,775,734.21
    应收利息
    应收股利
    其他应收款                                              27,371,789.94          24,229,348.50
    存货                                                    82,412,443.41          76,103,381.77
    一年内到期的非流动资产
    其他流动资产
      流动资产合计                                     1,546,882,057.95        1,566,629,753.16非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资                                         189,844,226.14           189,861,727.71
    投资性房地产
    固定资产                                             669,282,567.66           667,058,083.89
    在建工程                                             299,213,003.31           106,627,059.10
    工程物资
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                                91,339,400.66          94,426,154.49
    开发支出                                                18,000,000.00          18,000,000.00
    商誉
    长期待摊费用
    递延所得税资产                                         1,933,752.88            1,777,168.41
    其他非流动资产                                        51,151,590.03           60,097,739.35
      非流动资产合计                                   1,320,764,540.68        1,137,847,932.95
         资产总计                                      2,867,646,598.63        2,704,477,686.11
    公司法定代表人: 肖伟           主管会计工作负责人:陈友龙           会计机构负责人:焦晓杉
        江苏康缘药业股份有限公司(股票代码:600557)                       2013 年第三季度报告
                                  母公司资产负债表(二)
                                       2013 年 9 月 30 日
    编制单位: 江苏康缘药业股份有限公司
                                                 单位:元 币种:人民币       审计类型:未经审计
                   项 目                                期末余额                 年初余额流动负债:
    短期借款                                             410,000,000.00          442,000,000.00
    交易性金融负债
    应付票据                                            100,000,000.00            99,500,000.00
    应付账款                                            145,488,407.52           100,333,155.53
    预收款项                                              8,427,367.41            24,913,288.18
    应付职工薪酬                                          1,233,272.44             1,566,658.22
    应交税费                                             51,703,893.76            32,472,347.65
    应付利息                                              1,007,168.05             1,117,978.19
    应付股利                                              7,597,770.53
    其他应付款                                          146,469,244.36           146,021,209.51
    一年内到期的非流动负债                               23,000,000.00            58,000,000.00
    其他流动负债                                         29,973,074.73            31,357,449.78
      流动负债合计                                      924,900,198.80           937,282,087.06非流动负债:
    长期借款                                             155,000,000.00          170,000,000.00
    应付债券
    长期应付款
    专项应付款                                              2,781,854.00           3,026,346.00
    预计负债
    递延所得税负债
    其他非流动负债
      非流动负债合计                                     157,781,854.00         173,026,346.00
          负债合计                                     1,082,682,052.80       1,110,308,433.06所有者权益(或股东权益):
    实收资本(或股本)                                   415,646,691.00          415,646,691.00
    资本公积                                             268,152,669.08          268,152,669.08
    减:库存股
    专项储备
    盈余公积                                             139,629,188.21          139,629,188.21
    一般风险准备
    未分配利润                                           961,535,997.54         770,740,704.76
        所有者权益(或股东权益)合计                   1,784,964,545.83       1,594,169,253.05
    负债和所有者权益(或股东权益)总计                 2,867,646,598.63       2,704,477,686.11
    公司法定代表人: 肖伟           主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉
              江苏康缘药业股份有限公司(股票代码:600557)                     2013 年第三季度报告
      4.2
                                                 合并利润表
      编制单位: 江苏康缘药业股份有限公司
                                                   单位:元 币种:人民币      审计类型:未经审计
                                  本期金额           上期金额     年初至报告期期末 上年年初至报告期
            项目
                                (7-9 月)        (7-9 月)      金额(1-9 月)  期末金额(1-9 月)
    一、营业总收入                590,062,173.06     530,817,908.46 1,637,665,925.12      1,364,701,390.59
    其中:营业收入              590,062,173.06     530,817,908.46 1,637,665,925.12      1,364,701,390.59
    二、营业总成本                501,420,899.34     442,280,663.97 1,400,136,270.63      1,159,877,271.60
    其中:营业成本              149,635,081.44     154,445,769.85     419,418,347.62      338,654,829.45
        营业税金及附加          9,561,096.37       8,741,173.33       26,021,707.72       22,856,026.78
        销售费用              249,503,005.23     225,691,429.20     685,489,604.56      570,449,854.49
        管理费用               79,224,641.40      37,364,838.61     230,487,430.73      184,378,252.08
        财务费用               12,951,051.88      15,257,848.39       37,726,473.44       41,241,956.64
        资产减值损失                546,023.02         779,604.59        992,706.56        2,296,352.16
    加:公允价值变动收益
        投资收益                    72,642.12         -18,137.52         416,024.45             31,557.51
        其中:对联营企业和
                                   -14,083.90                            -17,501.57合营企业的投资收益
    三、营业利润                   88,713,915.84      88,519,106.97      237,945,678.94       204,855,676.50
    加:营业外收入               18,244,996.12       7,882,398.42       29,197,156.82        14,941,681.97
    减:营业外支出                1,368,871.25          55,724.81        2,345,963.52           714,295.06
    四、利润总额                  105,590,040.71      96,345,780.58      264,796,872.24       219,083,063.41
    减:所得税费用               15,891,102.87      14,505,899.64       39,553,025.81        32,576,430.36
    五、净利润                     89,698,937.84      81,839,880.94      225,243,846.43       186,506,633.05
    归属于母公司所有者的净
                               88,880,581.39      80,951,180.44      223,147,142.65       184,420,738.63利润
    少数股东损益                     818,356.45         888,700.50       2,096,703.78         2,085,894.42六、每股收益:
    (一)基本每股收益                      0.21               0.19              0.54                  0.44
    (二)稀释每股收益                      0.21               0.19              0.54                  0.44七、其他综合收益
    八、综合收益总额               89,698,937.84      81,839,880.94      225,243,846.43       186,506,633.05
    归属于母公司所有者的综
                               88,880,581.39      80,951,180.44      223,147,142.65       184,420,738.63合收益总额
    归属于少数股东的综合收
                                   818,356.45         888,700.50       2,096,703.78         2,085,894.42益总额
        公司法定代表人: 肖伟             主管会计工作负责人:陈友龙       会计机构负责人:焦晓杉
           江苏康缘药业股份有限公司(股票代码:600557)                     2013 年第三季度报告
                                           母公司利润表
    编制单位: 江苏康缘药业股份有限公司
                                                 单位:元 币种:人民币      审计类型:未经审计
                                本期金额           上期金额     年初至报告期期末 上年年初至报告期
          项目
                              (7-9 月)        (7-9 月)      金额(1-9 月)  期末金额(1-9 月)
    一、营业收入                504,335,836.73     424,665,443.36 1,370,827,788.83 1,125,645,093.17
    减:营业成本              130,949,419.27     116,828,113.30     364,759,186.65    289,506,650.43
      营业税金及附加          7,940,960.66       7,264,149.86       21,544,273.05     18,763,802.58
    销售费用               194,190,342.43     173,148,611.65     522,076,335.45    431,953,753.68
    管理费用                71,515,121.67      27,732,364.75     197,014,735.24    153,073,091.63
    财务费用                11,168,642.79      13,290,401.34       31,429,303.72     34,413,155.35
    资产减值损失                 545,993.34         777,358.27      1,044,335.60      2,076,709.64
    加:公允价值变动收益
    投资收益                   -14,083.90         -18,137.52        -17,501.57            31,557.51
      其中:对联营企业和
                                -14,083.90                           -17,501.57合营企业的投资收益
    二、营业利润                 88,011,272.67      85,606,306.67    232,942,117.55      195,889,487.37
    加:营业外收入             17,110,626.12       7,623,028.66     27,688,786.82       14,616,545.38
    减:营业外支出              1,303,354.17           1,500.00      2,275,407.66          499,750.78
    其中:非流动资产处置损失
    三、利润总额                103,818,544.62      93,227,835.33    258,355,496.71      210,006,281.97
    减:所得税费用             15,490,882.69      13,866,217.24     38,464,935.56       31,188,326.18
    四、净利润                   88,327,661.93      79,361,618.09    219,890,561.15      178,817,955.79五、每股收益:(一)基本每股收益(二)稀释每股收益六、其他综合收益
    七、综合收益总额             88,327,661.93      79,361,618.09    219,890,561.15      178,817,955.79
       公司法定代表人: 肖伟         主管会计工作负责人:陈友龙         会计机构负责人:焦晓杉
          江苏康缘药业股份有限公司(股票代码:600557)                       2013 年第三季度报告
    4.3
                                         合并现金流量表
                                           2013 年 1—9 月
    编制单位: 江苏康缘药业股份有限公司
                                               单位:元      币种:人民币    审计类型:未经审计
                                                             年初至报告期期末      上年年初至报告期
                         项目
                                                               金额(1-9 月)    期末金额(1-9 月)一、经营活动产生的现金流量:
      销售商品、提供劳务收到的现金                            1,873,422,731.76     1,406,664,278.45
      收到的税费返还                                                850,000.00           240,000.00
      收到其他与经营活动有关的现金                               51,628,296.24        79,878,621.44
        经营活动现金流入小计                                  1,925,901,028.00     1,486,782,899.89
      购买商品、接受劳务支付的现金                              314,084,423.79       286,810,186.28
      支付给职工以及为职工支付的现金                            209,877,972.32       215,829,209.64
      支付的各项税费                                            281,169,023.42       226,368,537.13
      支付其他与经营活动有关的现金                              835,388,937.91       662,287,169.42
        经营活动现金流出小计                                  1,640,520,357.44     1,391,295,102.47
          经营活动产生的现金流量净额                            285,380,670.56        95,487,797.42二、投资活动产生的现金流量:
      收回投资收到的现金                                         34,000,000.00          1,000,000.00
      取得投资收益收到的现金                                        433,526.02             46,158.90
    处置固定资产、无形资产和其他长期资产收回的现金净额                 53,594.00         32,892,155.00
      处置子公司及其他营业单位收到的现金净额                        382,400.00
      收到其他与投资活动有关的现金                                                     4,300,000.00
        投资活动现金流入小计                                     34,869,520.02        38,238,313.90
    购建固定资产、无形资产和其他长期资产支付的现金              262,292,297.57       171,774,421.92
      投资支付的现金                                             65,000,000.00
      支付其他与投资活动有关的现金                                7,966,504.82
        投资活动现金流出小计                                    335,258,802.39       171,774,421.92
          投资活动产生的现金流量净额                           -300,389,282.37      -133,536,108.02三、筹资活动产生的现金流量:
      吸收投资收到的现金                                                             -63,308,000.00
      取得借款收到的现金                                        450,000,000.00       660,500,000.00
      收到其他与筹资活动有关的现金                                                    43,000,000.00
        筹资活动现金流入小计                                    450,000,000.00       640,192,000.00
      偿还债务支付的现金                                        493,350,000.00       512,420,000.00
      分配股利、利润或偿付利息支付的现金                         49,472,743.65        57,761,652.98
      支付其他与筹资活动有关的现金                                5,530,217.50
        筹资活动现金流出小计                                    548,352,961.15       570,181,652.98
          筹资活动产生的现金流量净额                            -98,352,961.15        70,010,347.02
    四、汇率变动对现金及现金等价物的影响                                -56,185.14             5,985.37
    五、现金及现金等价物净增加额                                   -113,417,758.10        31,968,021.79
      加:期初现金及现金等价物余额                              342,150,797.10       201,714,625.85
    六、期末现金及现金等价物余额                                    228,733,039.00       233,682,647.64
      公司法定代表人: 肖伟            主管会计工作负责人:陈友龙        会计机构负责人:焦晓杉
          江苏康缘药业股份有限公司(股票代码:600557)                      2013 年第三季度报告
                                        母公司现金流量表
                                           2013 年 1—9 月
    编制单位: 江苏康缘药业股份有限公司
                                                单位:元      币种:人民币      审计类型:未经审计
                                                             年初至报告期期末 上年年初至报告期期
                         项目
                                                               金额(1-9 月)     末金额(1-9 月)一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                            1,532,064,535.51     1,140,283,543.95
    收到其他与经营活动有关的现金                               45,832,438.06        66,433,760.97
       经营活动现金流入小计                                  1,577,896,973.57     1,206,717,304.92
    购买商品、接受劳务支付的现金                              265,618,414.43       236,107,014.81
    支付给职工以及为职工支付的现金                            158,526,565.60       167,878,663.98
    支付的各项税费                                            236,094,975.37       183,587,530.79
    支付其他与经营活动有关的现金                              683,861,874.66       484,765,424.27
       经营活动现金流出小计                                  1,344,101,830.06     1,072,338,633.85
         经营活动产生的现金流量净额                            233,795,143.51       134,378,671.07二、投资活动产生的现金流量:
    收回投资收到的现金                                                                1,000,000.00
    取得投资收益收到的现金                                                               46,158.90
    处置固定资产、无形资产和其他长期资产收回的现金净
                                                                    53,594.00         32,892,155.00额
    处置子公司及其他营业单位收到的现金净额                        382,400.00
       投资活动现金流入小计                                        435,994.00        33,938,313.90
    购建固定资产、无形资产和其他长期资产支付的现金              232,939,926.45       112,160,818.96
    投资支付的现金
    取得子公司及其他营业单位支付的现金净额
    支付其他与投资活动有关的现金
       投资活动现金流出小计                                    232,939,926.45       112,160,818.96
         投资活动产生的现金流量净额                           -232,503,932.45       -78,222,505.06三、筹资活动产生的现金流量:
    吸收投资收到的现金                                                             -63,308,000.00
    取得借款收到的现金                                        263,000,000.00       493,000,000.00
    收到其他与筹资活动有关的现金
       筹资活动现金流入小计                                    263,000,000.00       429,692,000.00
    偿还债务支付的现金                                        345,000,000.00       393,000,000.00
    分配股利、利润或偿付利息支付的现金                         45,169,996.63        47,200,060.26
    支付其他与筹资活动有关的现金
       筹资活动现金流出小计                                    390,169,996.63       440,200,060.26
         筹资活动产生的现金流量净额                           -127,169,996.63       -10,508,060.26四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                                  -125,878,785.57        45,648,105.75
    加:期初现金及现金等价物余额                              307,680,839.04       146,727,209.10
    六、期末现金及现金等价物余额                                   181,802,053.47       192,375,314.85
      公司法定代表人: 肖伟         主管会计工作负责人:陈友龙          会计机构负责人:焦晓杉